chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient was present in the clinic on 6/30/2022 for his 1st dose of Moderna (6 months ? 5yrs formulation, lot number AS1414B). Client received the vaccine to his left thigh at 1406. Approximately 6 min post vaccination, Client?s guardian witnessed brief several second muscle tremors. Client?s guardian notified the observation nurse, RN. Approximately 9 min post vaccination, both guardian and observation nurse witnessed another episode. The nurse described the episode to this writer as a tremor in BL hands when extending out from the body, though the client remained responsive without decreased LOC. Observation nurse notified the Charge nurse and the Supervisor. Client was moved to the cot for further assessment. The clinical staff all witnessed another episode in which the client?s head and neck appeared to spasm and tremor (rapid, involuntary micromovements from side to side).  Again, the client remained alert and oriented, following instructions. A neurological assessment was conducted, grips were equal, pedal strength was equal, pupils were PERRLA. The client denied feeling unusual or ill and remained focused on his video.  The client?s face and skin were visualized, no s/s of swelling/rashes, although the client?s cheeks may have been slightly flushed. The client?s guardian also confirmed that the client?s face was WNL. Vital signs were WNL, see below:  ? First set of vitals was taken at 14:27: BP (104/64), HR (106), Sp02 RA (98%)     ? Second set of vital was taken at 14:37: BP (106/41), HR (114), Sp02 RA (98%)   The client?s lungs were auscultated; assessment was complicated by the client?s inability to stay still, but there may have been slight congestion upon exhalation. This cleared upon second assessment. No s/s dyspnea/SOB were noted.  The Clinical Site Supervisor called the on-call physician. Upon evaluating the results of assessment, he reported that he did not believe the client was experiencing seizures or an allergic reaction. He advised that the client may stay for another 30 minutes if the client?s guardian wished, but it was not necessary for the safety or well-being of the client. He also advised that, if the tremors continue, the client?s guardian should seek out care from her child?s primary care physician. Otherwise, he was comfortable if the client?s guardian wished to exit.   The client?s guardian was educated on when to seek medical care, s/s of anaphylactic reactions in children. She verbalized understanding and reported that she was comfortable exiting at this time. She reported that she would monitor her child at home and that she had epinephrine injectors s/t to an existing nut allergy. The client remained stable during the entire episode of care and exited at 1452 with his guardian and sibling.
heart palpitations lasting for 3 months; fever, chills, vomiting, loose stools, nausea, arm pain and swelling, fatigue, headache, muscle pain, joint pain for 2 days treated with ibuprofen and tylenol not very successfully
1. Weak 2. Shortness of Breath SpO2 89% 3. Lightheaded 4. Flush and feeling hot 5. Mild tremors  Onset of symptoms within 15-20 minutes post administration.  Provided Oxygen 4L/min
Child received above listed vaccines 11-20-08 at routine WCC visit at 12 noon. Child developed tactile temp 11-21-08 around 1pm followed by pruritus & hives on face, back, legs. Child was concurrently less active, more sleepy. T 100.7 at 19:41 at presentation to ED. Exam revealed wheals & decreased activity - nontoxic appearance. BENADRYL administered also TYLENOL.
Four minutes after receiving the egg free flu shot patient began to feel a rush of heat.  She started to experience redness at the injection site along with small hives. Her lips began to feel itchy and she began feeling shot of breath.  Patient was given Benadryl in the office - with no improvement.  An ambulance was called and the patient was taken to the hospital.
This spontaneous report as received from a registered nurse refers to a immunocompromised patient of unknown age (gender not reported). The nurse reported that the patient was administered a first dose of PNEUMOVAX23 (lot#, route and dose not reported) on an unspecified date in August 2006 and was revaccinated with PREVNAR 13 (manufacturer unknown) (lot#, route and dose not reported) on an unspecified date in August 2013. The patient's unspecified physician requested that the patient be vaccinated again with PNEUMOVAX23. A second dose of PNEUMOVAX23 has not been administered at this time. No adverse effects reported. Additional information has been requested.
terribly sick; Initial information received on 10-Feb-2022 regarding an unsolicited valid Social Media non-serious case received from a consumer/non-hcp.  This case involves an unknown age and unknown gender patient who experienced terribly sick while receiving vaccine INFLUENZA VACCINE.   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date, the patient received a  dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number, dose , frequency, strength and expiry date was unknown) via unknown route in unknown administration site for prophylactic vaccination. Batch number and expiration date were requested.  On an unknown date the patient developed a non-serious event "terribly sick" (illness) (unknown latency) following the administration of INFLUENZA VACCINE.  Action taken with INFLUENZA VACCINE (INFLUENZA VACCINE) was not applicable.  It was not reported if the patient received a corrective treatment for the event (terribly sick).  At time of reporting, the outcome was Unknown for the event terribly sick.
Nausea, no appetite 1.5 hour later, explosive diarrhea 5-6 hours later (x3), fever, shaking, chills (7 hours later...for 3 hours). I was given the geriatric dose... there were two identification numbers on the 2 papers on the pharmacy Prescription printed RX 6410170 N it says that it was FLUAD 2018-2019 0.5 MI  Inj Seqi Influenza Vac Type A&B Surfa Lot# yf36905 exp 5/16/2019 08/7/2015 given: on the yellow paper, handwritten (Pharmacist) wrote: vaccine FLUAD; Lot No 250790, Site of Inj. L7; Exp Date 4-30-2019; rt of admin IM, MFR Seqirus. Vis Version 8/7/2015. Dosage 0.5.
First swelling occurred at injection site 48 hours after injection Baseball size lump with redness.  Very painful and tender to touch. Also, hot to the touch.  Seven days after injection exactly, neurological issues started.  Numbness and tingling on entire left side of body, in head and left side of face.  Since has moved also to right side.  Buzzing, hot spots.  Neuropathy. Also, pain in muscles and nausea.
According to mom at approx. 7:30 child called from friends home that he was feeling faint, short of breath, pain in left side of chest and arm. Went to MD for examination - no meds or treatment were given.
9 days after the vaccination, the area of my arm where the vaccine was injected became red, swollen and inflamed in a circular area slightly larger than a quarter. There is mild pain and moderate itching. The area feels firmer than the surround areas and is warm to the touch. It is clearly visible from a distance of around 10 ft. I just began experiencing symptoms approximately 2 hours ago, an am monitoring the situation.
Fatigue; Fever; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 05Apr2021 at 14:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic pain, spine fracture with multiple disc herniations. The patient was allergic to sulfa drugs, penicillin and bee stings. Prior to vaccination, the patient was not diagnosed with COVID -19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. The patient previously took bupropion, venlafaxine and acetaminophen and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208) via an unspecified route of administration in the left arm on 14Mar2021 at 14:00 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. On 06Apr2021 at 02:00, the patient experienced fatigue and fever. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the fatigue and fever which included treatment with MOTRIN 800mg, thrice daily. The clinical outcome of the events fatigue and fever were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. The patient's medical history and concurrent condition were not reported. On 29-DEC-2015 the patient was vaccinated with VARIVAX (strength, dose, route unknown) (lot# L019130, expiration date 27-MAY-2015 and lot# L026407, expiration date 15-JUL-2015) which were improperly stored (Temperature: 9.5 F, Time frame: 2 hours). No adverse effects were reported. This was one of several reports received from the same source. Additional information has been requested.
This spontaneous report as received from a nurse practitioner refers to a female patient of unknown age. The patient was vaccinated with the first dose of GARDASIL in February 2010, with the second dose in April or May 2010 and the third dose would be administered in the vaccination schedule on 11-OCT-2012. No other co-suspects were reported. No concomitant medications were reported. No adverse effect reported. Additional information has been requested.
Rashes, red, warm-to-touch, a little swollen and sore around the area of the injection site. I noticed it the day after the vaccine 01/22/2022. There was also a little weakness and muscle ache. I didn't feel like getting up and doing anything. I had a heavy feeling in my arm and soreness later that day of vaccine 01/21/2022. It is still red, warm-to-touch, rash (seems localized) and sore until today 01/24/2022. I'm keeping a close eye and observing.
extreme fatigue     102 Fever The First day   3-5-2021 101.5 Fever the Second day 3-6-2021 Nausea  3-4-21  - 3-5-2  - 3-6-21    3-7-21.
Patient mentioned that she had her second COVID vaccination earlier today at 0630 and hasn't been feeling well since. She had breakfast around 0700 this morning.  Patient was cleaning off a bed when she stated that she was nauseous and dizzy.  She had a syncopal episode from standing, hitting her head on the floor.  LOC for a few seconds and then awake.  BP-138/90, FS-93.
This spontaneous report was received from a registered nurse and refers to 4-year-old patient of unknown gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 11-MAY-2017, the patient was vaccinated with improperly stored dose of PROQUAD lot # L046506, expiration date of 17-MAY-2017 (dose and route of administration were not reported). The vaccine was reconstituted with properly stored sterile diluent (DILUENT MRK). Administered dose of vaccine experienced the temperature excursion between 6 and 14 degrees F for 30 minutes on 03-FEB-2017. No previous temperature excursion occurred. No product quality complaint was involved. No adverse effects were reported. Digital Data logger was involved. This is one of several reports received from the same source. Additional information is not expected as all relevant information has already been received.; Sender's Comments:  US-009507513-1704USA010916:
The associate's right arm turned light red along with tiny bumps. The associate reported feeling achy and stiff which felt like nerve aggravation. These symptoms cleared up within 36 hours. The patient did not seek medical attention and did not receive any medications to treat the symptoms.
patient sitting in the chair and 5 minutes after vaccine patient stated she was experiencing a warm feeling on the right side of her neck running from the claivicle  area to the side of her ear and a tightening feeling.  vitals were taken 3:33 b/p 110/65 p 67  r18 sat 99%  2nd at 3:40 b/p 111/66 p 68 r 18 sat 99% 3rd at 3:50nb/p 112/76 p 94 r 18 sat 98% patient stated she was feeling much better patient was educated and encouraged to go to the nearest ER if any other side effects should occur patient was wheeled to the main entrance with husband to be released to go home safely.
This spontaneous report was received from a 53 year old female patient, regarding himself. Patient's pertinent medical history was reported as acid reflux, hepatitis c and prediabetes with no changes. Patient was allergic to novacaine, since it caused her heart rate to increase. On 10-FEB-2015 the patient vaccinated with PNEUMOVAX 23 for the prevention of pneumonia. Concomitant therapies included temazepam, oxybutynin (Manufacturer unknown) and pantoprazole. After receiving the PNEUMOVAX 23, the patient experienced her left leg became numb. Consumer sought medical attention and went to emergency room, and was seen by an unspecified physician. Computerised tomography (CT) scan was performed on an unspecified date in February 2015 and after the review of CT scan, physician informed consumer, that she did not have a stroke. Consumer was discharged to follow up with primary care physician and a neurologist. On an unspecified date, consumer reported that the numbness had improved. However, she had intermittent left calf discomfort and the intensity of the left leg numbness varied and occasionally extended to the ankle. On 17-FEB-2015, she experienced slight chest pain when she resumed exercise at the gym. Chest pain resolved, with no treatment. The outcome of the left leg numbness and intermittent left calf discomfort was unknown. No product quality complaint (PQC) was involved. Causality assessment was not provided. Additional information has been requested.
After I gave the patient his covid19 shot. the patient told me that he doesn't feel good. he had injection site reaction and his arm bled. I prepared for him the epipen shot but he refused it. he became pale and was exhaling loudly. he preferred to sit down on the floor. his blood pressure was also high. the 911 arrived the location but the patient refused to go to hospital. and left the pharmacy with one of his family members telling us that he is fine. he also was conscious and talking to me all the time.
Injection site redness; Swollen lymph nodes; Lymph node pain; Bumps on the left arm; Injection site itching; large red blotchy patch around injection site, very itchy; This spontaneous case was reported by a consumer and describes the occurrence of MASS (Bumps on the left arm), RASH PRURITIC (large red blotchy patch around injection site, very itchy), INJECTION SITE PRURITUS (Injection site itching), INJECTION SITE ERYTHEMA (Injection site redness) and LYMPHADENOPATHY (Swollen lymph nodes) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Sulfonamide allergy (Allergic to Sulfa), Drug allergy (Allergic to gabapentin), Food allergy (Food allergy to Bananas) and Epilepsy since 30-Jun-2015. Concomitant products included PREGABALIN (LYRICA) for Epilepsy.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, the patient experienced RASH PRURITIC (large red blotchy patch around injection site, very itchy). On 06-Apr-2021, the patient experienced MASS (Bumps on the left arm) and INJECTION SITE PRURITUS (Injection site itching). On 07-Apr-2021, the patient experienced INJECTION SITE ERYTHEMA (Injection site redness), LYMPHADENOPATHY (Swollen lymph nodes) and LYMPH NODE PAIN (Lymph node pain). On 01-Apr-2021, RASH PRURITIC (large red blotchy patch around injection site, very itchy) had resolved. At the time of the report, MASS (Bumps on the left arm), INJECTION SITE PRURITUS (Injection site itching), INJECTION SITE ERYTHEMA (Injection site redness), LYMPHADENOPATHY (Swollen lymph nodes) and LYMPH NODE PAIN (Lymph node pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided.   This case was linked to MOD-2021-251800 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 08-Jul-2021: Patient details, medical history, and event details was updated..
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in an 82-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Oct-2021 at 9:51 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 27-Oct-2021 at 9:51 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  Age of patient was reported as 82.28 for dose administered on 27-Oct-2021.  Batch number 035C21A underwent temperature excursion on 27-Oct-2021 with temperature 29 degrees Fahrenheit from 09:00 AM to 10:00 AM. This vial was moved to fridge on 05-Oct-2021 and beyond use date for the vial was reported as 04-Apr-2021. Product moved to clinic on 27-Oct-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour. No treatment medications were reported.
We were told by the administering healthcare worker that approximately 20% experienced symptoms, and someone of her advanced age would probably only experience a sore arm. Nearly everyone in the retirement home was extremely ill after the second dose; most of the administrative staff went home sick; skeleton crew pulled double shifts caring for residents with extreme "blow-out" diarrhea and debilitating nausea. One patient reported temporary paralysis. Men complained of sore arms but women couldn't get out of bed. We were prepared with prophylactic anti-emetic meds and avoided diarrhea. However, patient had headaches and nausea for a week; refusal to eat/drink put patient at risk for dehydration and kidney issues; fasting  exacerbated confusion and put patient at risk of harm (wandering, falling, etc.) Patient is still lethargic and confused, has started eating again but only minimally, a few bites. Strongly regret vaccinating.
Patient had physical exam on 4/16/03. Had routine immunization. Pt had another visit with MD on 4/18/03 for rechecking injection site swelling up. Cold compresses with relief.
Miscarriage occurred within 2 days of the vaccine. I have carried 2 out of 3 children to over 8 months, the first a live birth (greater than 7 lb) and the second ended in stillbirth (also greater than 7 lb). I have no history of miscarriage. This was my third pregnancy. I became pregnant in March with positive tests on 4/19, 4/20, and 4/21. I had the Covid vaccine 4/21 and by 4/23 was suddenly in pain and bleeding, which continued for six days, after which my body began to recover. Additionally, I began to suffer breathing trouble, waking in the night, heart pounding (no nightmares or fears) and gasping. Was prescribed two inhalers to recover.
Subject in pneumococcal vaccine trial, with severe COPD hospitalized w/ stroke. Vaccination took place 5/12/08. According to physician the relationship is 'none'.
Patient was administered the vaccine around 6:15 pm on 2/23/21 and she waited in the pharmacy recovery area for the full 15 minute time.  Patient called the pharmacy after she had just returned home (around 7 pm) and said her throat felt funny and she had a metallic taste in her mouth.  Confirmed no difficulty breathing at that point, but that her throat felt a "little thick".    As patient was already at home and not near the pharmacy area, recommended that she immediately go to ER to be seen as felt the delay of driving back to potentially get epi injection and then be sent to ER could be detrimental to the patient.  She confirmed that she would head to the nearest ER.
Reports of body ache, mild HA, left deltoid pain (site of vaccineation) this AM, 2/10/21 Pt had her 2nd Moderna COVID vaccine yesterday, pt felt fine and completed her work shift which is Mon-Wed 1400-0230. Denies previous COVID hx, allergies to previous vaccines, no previous illness. Pt denies any symptoms after 1st Moderna vaccine.
Patient didn't receive the second dose; This spontaneous case was reported by a non-health professional and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Patient didn't receive the second dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jul-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient didn't receive the second dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Patient didn't receive the second dose) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.  The patient did not experience any adverse events/reactions after first dose. She states that she still has not received the second dose.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: follow up received: outcome of the event was updated to not recovered, narrative information was updated.
This spontaneous report as received from a Doctor of pharmacy refers to a 40 year old male patient. On an unspecified date in 1978, the patient was vaccinated with the first and second doses of MMR II (dose, route and lot # not reported). The pharmacist reported that "now" in 2014, the patient had negative titers for MMR. The outcome of negative titers for MMR was unknown. Additional information has been requested.
After the booster my concussion symptoms regressed to poor memory, emotional, not sleeping, some vertigo